Original articles
Zhihao Fu, Hongchuan Liu, Lan Wang, Chuanfei Yu, Yalan Yang, Meiqing Feng, Junzhi Wang. A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3925-3934

A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
Zhihao Fua, Hongchuan Liub, Lan Wanga, Chuanfei Yua, Yalan Yanga, Meiqing Fengb, Junzhi Wanga
a. Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China;
b. Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China
Abstract:
T cell immunoglobulin and ITIM domain (TIGIT) is a novel immune checkpoint that has been considered as a target in cancer immunotherapy. Current available bioassays for measuring the biological activity of therapeutic antibodies targeting TIGIT are restricted to mechanistic investigations because donor primary T cells are highly variable. Here, we designed a reporter gene assay comprising two cell lines, namely, CHO-CD112-CD3 scFv, which stably expresses CD112 (PVRL2, nectin-2) and a membrane-bound anti-CD3 single-chain fragment variable (scFv) as the target cell, and Jurkat-NFAT-TIGIT, which stably expresses TIGIT as well as the nuclear factor of activated T-cells (NFAT) response element-controlled luciferase gene, as the effector cell. The anti-CD3 scFv situated on the target cells activates Jurkat-NFAT-TIGIT cells through binding and crosslinking CD3 molecules of the effector cell, whereas interactions between CD112 and TIGIT prevent activation. The presence of anti-TIGIT mAbs disrupts their interaction, which in turn reverses the inactivation and luciferase expression. Optimization and validation studies have demonstrated that this assay is superior in terms of specificity, accuracy, linearity, and precision. In summary, this reliable and effective reporter gene assay may potentially be utilized in lot release control, stability assays, screening, and development of novel TIGIT-targeted therapeutic antibodies.
Key words:    TIGIT    Therapeutic antibodies    Bioactivity determination    Reporter gene assay    Method validation   
Received: 2021-04-25     Revised: 2021-07-08
DOI: 10.1016/j.apsb.2021.09.011
Funds: This work was supported by the Major Scientific and Technological Special Project for “Significant New Drugs Development” (Grant No. 2018ZX09736016-007, China).
Corresponding author: Junzhi Wang,E-mail:wangjz_nifdc2014@163.com     Email:wangjz_nifdc2014@163.com
Author description:
Service
PDF(KB) Free
Print
0
Authors
Zhihao Fu
Hongchuan Liu
Lan Wang
Chuanfei Yu
Yalan Yang
Meiqing Feng
Junzhi Wang

References:
[1] Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature 2018; 562: 20-21
[2] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350-1355
[3] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168: 707-723
[4] Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol 2019; 20: 1425-1434
[5] Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019; 18: 197-218
[6] Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 1: 48-57
[7] Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 2009; 42: 17858-17863
[8] Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 2009; 3: 695-703
[9] Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol 2017; 1: 20-28
[10] Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev 2017; 1: 112-120
[11] Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016; 5: 989-1004
[12] Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 2018; 7: 723-732
[13] Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L. et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 2018; 16: 1675-1688
[14] Harjunpaa H, Blake SJ, Ahern E, Allen S, Liu J, Yan J. et al. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncoimmunology 2018; 7: e1445949
[15] Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K, et al. TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood 2018; 16: 1689-1694
[16] Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer cell 2014; 6: 923-937
[17] Harjunpaa H, Guillerey C. TIGIT as an emerging immune checkpoint. Cli Exp Immunol 2020; 2: 108-119
[18] Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM. et al. DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers 2019; 6: 877
[19] Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (Tira) plus atezolizumab (Atezo) versus placebo plus Atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol 2020; 38: 9503
[20] Dolgin E, Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol 2020; 9: 1007-1009
[21] Murano G, FDA perspective on specifications for biotechnology products-from IND to PLA. Dev Bio Stand 1997; 91: 3-13
[22] International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS. Fed Regist 1999; 159: 44928-44935
[23] Mire-Sluis AR, Progress in the use of biological assays during the development of biotechnology products. Pharm Res 2001; 9: 1239-1246
[24] Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 8: 3869-3875
[25] Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 2015; 5: 2046-2058
[26] Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, et al. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med 2016; 2: 167-176
[27] Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol 2018; 8: 3000-3007
[28] Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S. Melanoma cells control antimelanoma ctl responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermato 2016; 1: 255-263
[29] Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immuno Immunother 2017; 10: 1367-1375
[30] Tang W, Pan X, Han D, Rong D, Zhang M, Yang L. et al. Clinical significance of CD8+ T cell immunoreceptor with Ig and ITIM domains+ in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. Oncoimmunology 2019; 6: e1593807
[31] de Ines C, Cochlovius B, Schmidt S, Kipriyanov S, Rode HJ, Little M. Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. J Immunol 1999; 7: 3948-3956
[32] Yang ZM, Li EM, Lai BC, Wang YL, Si LS. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity. Biochem Cell Biol 2007; 2: 196-202
[33] Loh C, Carew JA, Kim J, Hogan PG, Rao A. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol Cell Biol 1996; 7: 3945-3954
[34] Badran BM, Wolinsky SM, Burny A, Willard-Gallo KE. Identification of three NFAT binding motifs in the 5′-upstream region of the human CD3gamma gene that differentially bind NFATc1, NFATc2, and NF-kappa B p50. J Bio Chem 2002; 49: 47136-47148
[35] Wang L, Yu C, Yang Y, Gao K, Wang J. Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies. J Pharm Biomed Anal 2017; 145: 447-453
[36] Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27: 591-619
[37] Griffin MD, Holman PO, Tang Q, Ashourian N, Korthauer U, Kranz DM, et al. Development and applications of surface-linked single chain antibodies against T-cell antigens. J Immunol Methods 2001; 1-2: 77-90
[38] Deuss FA, Gully BS, Rossjohn J, Berry R. Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J Bio Chem 2017; 27: 11413-11422
[39] Liu S, Zhang H, Li M, Hu D, Li C, Ge B, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 2013; 3: 456-464
[40] Bhagwat B, Cherwinski H, Sathe M, Seghezzi W, McClanahan TK, de Waal Malefyt R, et al. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods 2018; 456: 7-14
[41] Wang L, Yu C, Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv 2020; 39: 107466
Similar articles: